148 results about "Gastrointestinal fluids" patented technology

Disclosed in a controlled release sulfonylurea formulation. In certain embodiments, the invention comprises: (a) a core comprising: (i) a sulfonylurea or a pharmaceutically acceptable salt thereof; (ii) a pharmaceutically acceptable polymer; (b) a membrane surrounding the core which is permeable to the sulfonylurea and gastrointestinal fluid, wherein said dosage form provides a mean time to maximum plasma concentration (Tmax) of said sulfonylurea.

The invention relates to an Oral Delayed Immediate Release formulation comprising a compressed core containing one or more active substances surrounded with a coating, wherein release of active substance from the core is caused by rupture of the coating after a definite lag-time, said core comprising one or more immediate release carriers and having no substantial swelling properties upon exposure to gastrointestinal fluids. The invention further relates to formulations containing an Immediate Release formulation combined with one or more Oral Delayed Immediate Release formulations with different lag-times and to a method of preparing an Oral Delayed Immediate Release formulation.The Oral Delayed Immediate Release formulation may be used for the application of active substances whenever a certain lag-time before release is advantageous, such as in be the case of anti-asthmatics, anti-emetics, cardiotonics, vasodilators, anti-vertigo and anti-meniere compounds, anti-hypertensives, sedatives, anti-depressants, anti-anxiety compounds, cortico-steroids, general anti-inflammatory compounds, anti-inflammatory compounds for gastrointestinal use, anti-ulceratives, analgetics, anti-aritmics, anti-rheumatics, anti-arthritic compounds and anti-angina compounds.The Oral Delayed Immediate Release formulation may also be used for the application of biological active compounds such as proteins, peptides, enzymes, vaccines and oligonucleotides.

The invention relates to the technical field of microorganism, and discloses a Lactobacillus reuteri and its application. The preservation number of the Lactobacillus reuteri CCFM8631 is CGMCC No.14394; the level of mice peripheral neurotransmitter 5-hydroxytryptamine can be significantlyimproved; the rise of the mice peripheral blood testonsterone level and the abundant abnormity of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora by high glucose and high fatty diets are recovered; the tolerated simulative gastrointestinal fluid is rapidly planted in an intestinal tract, so as to significantly improve the pathological injury of metabolic syndrome mice liver and duodenum and rise of triglyceride and total cholesterol content in the serum by high glucose and high fatty diets are significantly improved; the Lactobacillus reuteri can be used for preventing, delaying or treating metabolic disorder such as metabolic syndrome, irritable bowel syndrome, and anxiety, depression and other metal diseases related to irritable bowel syndrome.

The invention discloses bifidobacterium bifidum capable of remarkably relieving constipation and application thereof and belongs to the technical field of microorganisms. The bifidobacterium bifidum CGMCC NO.13632 can well tolerate simulative gastrointestinal fluid, can be well attached to colon cancer cells HT-29, and can remarkably increase the water content of excrement of constipation mice and shorten the first tarry stool time. On the aspect of increasing the small intestine driving rate, the bifidobacterium bifidum CGMCC NO.13632 is superior to cathartic phenolphthalein, a best effect is shown, secretion of gastrointestinal regulatory peptide relevant to constipation in serum is also adjusted while constipation pathological factors are remarkably improved, and the bifidobacterium bifidum does not have toxic and side effects of medicine for treating constipation, and is a first choice for preventing and treating constipation. The bifidobacterium bifidum CGMCC NO.13632 is used for preparing pharmaceutical compositions and fermented food for relieving constipation, and has very wide application prospects.

The invention discloses bifidobacterium longum and the application thereof and belongs to the technical field of biologics. The invention provides a bifidobacterium longum YS108R strain which has thecharacteristic of generating viscous exopolysaccharide, and has a remarkable improvement function on DSS (Dextran Sulfate Sodium) induced mouse colitis models. The strain has a relatively good capability of enduring simulated gastrointestinal fluids, is capable of remarkably reducing disease activity indexes of mice in the DSS induction period, and has an effective protection function on colon tissue. In addition, the bifidobacterium longum YS108R disclosed by the invention is separated from intestinal florae of healthy people, is free of toxic and/or side effects on human bodies, and has certain advantages when being compared with conventional medicine treatment. The strain can be used for preparing probiotic powder, fermented milk, and the like, and has wide market prospects.

A method of reducing the risk of alcohol-induced dose-dumping of a therapeutically active ingredient comprising administering to human subjects who have ingested alcohol an oral controlled release tablet; said tablet comprising:

• • a core comprising
    • an upper compressed layer comprising a swelling agent, and
    • a lower compressed layer comprising at least one therapeutically active ingredient, and pharmaceutically acceptable excipient wherein at least one excipient is a release rate controlling excipient and wherein the percent by weight of excipients that are soluble in alcohol does not exceed 35% by weight of the layer and;
  • a coating surrounding the said core, the coating comprising a polymer insoluble in an aqueous medium comprising from 0% v/v to 40% v/v of alcohol, whereby upon contact with aqueous gastrointestinal fluids, the upper compressed layer swells to cause removal of the coating from the upper surface of the upper compressed layer and then said upper layer disintegrates allowing the release of the active ingredient from the defined surface area of the upper surface of said lower compressed layer with the coating covering its bottom and side surfaces.

The present invention claims and discloses a pharmaceutical composition suitable for oral administration, in form of an emulsion pre-concentrate, comprising (i) one or more NO-releasing NSAID(s); (ii) one or more surfactants; (iii) optionally an additional oil or semi-solid fat; said composition forming an in-situ oil-in-water emulsion upon contact with gastrointestinal fluids. The composition may optionally also comprise one or more short-chain alcohols. Also within the scope of the invention is a combination with a proton pump inhibitor. The pharmaceutical composition is useful in the treatment of pain and inflammation. Further within the scope of the invention is kit comprising a pharmaceutical composition according to the invention in a unit dosage form, in combination with a proton pump inhibitor, and said proton pump inhibitor is enteric coated

The invention discloses a novel insulin-phospholipid-chitosan self-assembled microparticle carrier and a drug delivery system thereof, wherein the mass ratio of insulin to phospholipid is 1 to (3-100); and the mass ratio of chitosan to the phospholipid is 1 to (5-50). The self-assembled microparticle carrier disclosed by the invention is prepared by preparing an insulin-phospholipid compound from the insulin and a proper amount of the phospholipid material in a special environment, injecting a non-aqueous solvent organic phase of the insulin-phospholipid compound to an aqueous-phase solution of the chitosan, and self-assembling in a warm stirring condition, so that the insulin-phospholipid-chitosan microparticle carrier is formed. The insulin-phospholipid-chitosan microparticle carrier disclosed by the invention is free from the addition of a cross-linking agent, is represented in a circular or elliptic form and has a multilayer capsule structure; the grain size distribution of the microparticle carrier is 50-5000nm and a drug entrapment rate reaches 70% or above; the microparticle carrier is good in quality stability in a gastrointestinal fluid environment and low in burst release; the microparticle carrier can break through the limitation of an enzyme barrier and a membrane barrier; and the microparticle carrier is used for preparing insulin non-injection drug delivery systems such as oral drug delivery, mucosal drug delivery, percutaneous drug delivery and the like.

The invention belongs to the technical field of microbial fermentation, and in particular, relates to a clostridium butyricum inoculum with strong butyric acid resistance and stress resistance and anapplication thereof. Clostridium butyricum is specifically clostridium butyricum LXKJYB-1, and has the preservation number of CCTCC NO:M 2017485. The strain LXKJYB-1 has the characteristics of high fermentation level, high organic acid yield, inhibition of a variety of intestinal pathogens, and high tolerance capacity to gastrointestinal fluid, cholate and damp heat. The strain and the inoculum prepared therefrom are suitably applied for livestock and poultry breeding, increases the efficiency of breeding, and produces no-resistance livestock and poultry products.

The invention provides Lactobacillus rhamnosus M9 separated from breast milk. The microbial preservation number is CGMCC No.16002, and the Lactobacillus rhamnosus M9 has the excellent tolerance of gastrointestinal fluid and the good cholate tolerance, and has the basic condition as probiotics. The Lactobacillus rhamnosus M9 has the effect of enhancing immunity resistance, improving intestinal flora diversity and enhancing the intestinal flora stability, and the Lactobacillus rhamnosus M9 can be added into various common foods, healthcare products and the like as probiotics.

A pharmaceutical composition having improved solubility comprising a hydrophobic drug or pharmaceutically acceptable salt thereof and a compound having at least one carboxylic acid moiety, wherein the molar ratio of the compound having at least one carboxylic acid moiety to the hydrophobic drug or pharmaceutically acceptable salt thereof is from about 0.1:1 to about 25:1. The pharmaceutical composition exhibits rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.

The present invention claims and discloses a pharmaceutical composition suitable for oral administration, in form of an emulsion pre-concentrate, comprising (i) a compound of formula (I); (ii) one or more surfactants; (iii) optionally an oil or semi-solid fat; said composition forming an in-situ oil-in-water emulsion upon contact with aqueous media such as gastrointestinal fluids. The composition may optionally also comprise one or more short-chain alcohols. The pharmaceutical composition is useful in the treatment of pain and inflammation.

The present invention provides a new application of lactobacillus paracausei K56 capable of adjusting gastrointestinal flora balance. The lactobacillus paracasei (lactobacillus paracausei subsp.paracasei) has a preservation number of DSM27447. The strain of the single bacteria has ability to significantly promote growth of intestinal bifidobacteria and lactic acid bacteria, can inhibit desulphovibrio and/or enterobacter, can inhibit helicobacter pylori and/or escherichia-shigella genera, and can tolerate stress environment of simulated gastrointestinal fluid in vitro. Mouse experiments show that the strain has no oral acute toxicity and no antibiotic resistance, is safe and can be used for food processing.

The invention relates to a preparation method of a microencapsulated Enterococcus faecium live bacterium preparation and application of the preparation in breeding. The method employs a technological process of ''fermentation-coating-fermentation''. By adding 2g/L calcium chloride to a fermentation medium and conducting drying at 45DEG C, a microencapsulated Enterococcus faecium solid product with good sphericity and uniform size can be obtained, and its viable count can reach 11.57lgCFU/g. Compared with free Enterococcus faecium solid products, the microencapsulated Enterococcus faecium live bacterium preparation has stronger ability to tolerate a high temperature of 80DEG C and a simulated gastrointestinal fluid. After storage for 2 months under a normal temperature condition, the viable count basically has no change. The microencapsulated Enterococcus faecium live bacterium preparation has a simple pre-fermentation coating preparation process, good product appearance, strong stress resistance, high stability, and high encapsulation efficiency. Being use as a high activity microecological agent for feeding in actual production, the microencapsulated Enterococcus faecium live bacterium preparation can inhibit propagation of intestinal spoilage bacteria and pathogenic bacteria and intestinal infection, reduce the diarrhea rate, promote digestive absorption of nutrients, enhance immunity, improve feed intake and feed conversion rate, as well as lower feed-meat ratio.

The invention discloses lactobacillus rhamnosus and an application thereof. The lactobacillus rhamnosus is named as lactobacillus rhamnosus AU9260 in taxonomy, and the preservation number of the lactobacillus rhamnosus is CGMCC No.21662. The strain has excellent in-vitro probiotic characteristics such as simulated gastrointestinal fluid tolerance, bacteriostatic activity, adhesion to Caco-2 cells and the like, and is preliminarily judged to be safe. In addition, the strain has a potential function of relieving and/or preventing allergic diseases of hosts, can significantly reduce histamine, specific IgE and cell factors in serum of mice induced and sensitized by beta-lactoglobulin, and can also protect damage to intestinal mucosa structures of the mice caused by allergy and regulate intestinal flora structures. The lactobacillus rhamnosus can be used as foods and/or health-care foods with a desensitization effect.

The present disclosure provides oral drug dosage forms comprising: (a) an erodible non-stimulant material admixed with an ADHD non-stimulant; and (b) an erodible stimulant material admixed with an ADHD stimulant, wherein the erodible non-stimulant material admixed with the ADHD non-stimulant is embedded in a substrate material, and wherein upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a desired non-stimulant release profile and the ADHD stimulant is released according to a desired stimulant release profile. In some embodiment, the ADHD non-stimulant is released according to a sustained release profile. In some embodiments, the ADHD stimulant is released according to an immediate release profile. The oral drug dosage forms of the present disclosure are useful for the treatment of attention deficit hyperactivity disorder (ADHD). Also provided herein are methods of designing and manufacturing the oral drug dosage forms described herein.

Presented herein are polymeric cellular dosage forms exhibiting improved immediate release properties, while maintaining high uniformity and satisfactory mechanical properties (e.g., to permit necessary handling). An exfoliating polymeric cellular dosage form is described herein that can be cost-effectively manufactured via batch or even non-batch (continuous or semi-continuous) melt processing. The solid dosage forms have a unique cellular microstructure featuring a number of open, interconnected cells. The cell walls contain the active ingredient(s) as well as an excipient that swells in the presence of a physiological fluid such as gastrointestinal fluid and/or saliva under physiological conditions.

The invention discloses a lactic acid bacteria formula for preventing acute and chronic alcoholic liver injury and application thereof. Lactobacillus plantarum KLDS1.0344 and lactobacillus acidophilusKLDS1.0901 have good gastrointestinal fluid tolerance simulating capacity, have certain adhesion capacity to HT-29 cells and have basic probiotic characteristics; the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 can prevent acute alcoholic liver injury; and the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 can prevent chronic alcoholic liver injury. Specifically, the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 have the functions of reducing the liver index, improving the intestinal barrier, improving the liver function, reducing the inflammation level in the liver, increasing the content of short-chain fatty acid in the intestinal tract, reducing protein expression of CYP2E1 in the liver and the like.

The invention belongs to the technical field of medicines, and in particular relates to a nanosuspension of annonaceous acetogenin drugs prepared from such amphiphilic stabilizers as mPEG PCL, mPEG PLA, mPEG PLGA, mPEG DSPE, mPEG Chol, SPC, Tween80, BSA, TPGS and the like, as well as a preparation method and an application of the nanosuspension. The annonaceous acetogenin total lactone nanosuspension is prepared by virtue of a solvent precipitation-ultrasonic injection method, and according to a prescription, the proportioning ratio of the annonaceous acetogenin drugs to the stabilizer is at 1 to (0.02-10) (in percentage by weight). The prepared annonaceous acetogenin nanosuspension can reach a load-loading capacity to 90% to the greatest extent and can reach a minimum grain size to 123.2nm, and the nanosuspension is good in polydispersity. The nanosuspension is stable in both gastrointestinal fluid and plasma, and the nanosuspension is applicable to oral administration and injection administration; the nanosuspension has a good in-vitro sustained-release effect and is free from burst release; the nanoparticle, in comparison with a crude drug solution, is more obvious in tumor cell inhibitory rate in vitro; the nanosuspension, in in-vivo tissue distribution, shows tumor passive targeting; therefore, the nanosuspension is beneficial for enhancing efficacy and reducing toxic and side effects. Meanwhile, an in-vivo efficacy experiment shows that the nanosuspension is outstanding in antineoplastic efficacy, and the nanosuspension has a broad development prospect.

The invention relates to a suspension composition containing lysozyme and florfenicol, which is a microemulsion solution prepared from the lysozyme, the florfenicol, tween-80, sodium citrate, methylparaben, propylene glycol and water for injection. The composition adopts compatibility of the lysozyme and the florfenicol, not only enlarges the antimicrobial spectrum, but also has high efficiency, low toxicity, less residues and drug resistance prevention; and the prepared suspension not only can solve the problem that the florfenicol is hardly soluble in water, improves the biological utilization of the florfenicol, but also protects the activity of the lysozyme in gastrointestinal fluid, and plays a slow release effect on the lysozyme and the florfenicol to ensure that the medicament maintains long-term effective blood concentration in vivo, is integrated with instant effect, high efficiency and long action, and can be used for treating mycoplasma gallisepticum infections of livestock and poultry.

The invention discloses lactobacillus fermentum JX306 with an antioxidant function and application thereof, and belongs to the technical field of bioengineering. The lactobacillus fermentum JX306 hasa high DPPH free radical and hydroxyl radical scavenging ability, high reducing power, a high Fe2+ chelating ability, a favorable anti-lipid peroxidation ability, and favorable bile salt tolerance, gastrointestinal fluid resistivity and hydrogen peroxide tolerance; and the glutathione peroxidase activity can be remarkably improved, the malondialdehyde level is reduced, the levels of five antioxidant enzymes such as TR3, Prdx1, Gsr, Gpx1 and a nuclear transcription factor Nrf2 are remarkably improved, and the D-gal induced histopathological lesion can be remarkably relieved. The lactobacillus fermentum JX306 provided by the invention plays a big role on improving the oxidation resistance of food with the lactobacillus fermentum JX306 as a fermenting microbe, and has a wide application prospect.

The invention discloses application of bifidobacterium longum subsp.infantis. The bifidobacterium longum subsp.infantis is bifidobacterium longum subsp.infantis CCFM687, and the bifidobacterium longumsubsp.infantis CCFM687 can be used for preparing food or drugs capable of tolerating gastrointestinal fluids, relieving autism and adsorbing PCBs (polychlorinated biphenyls), enhance autonomic behaviors and exploratory behaviors caused by the autism in unfamiliar environments, relieve social communication obstacles caused by the autism, relatively remarkably improve stereotyped behaviors caused by the autism, enhance cognitive ability of autism for new objects, improve behavior despair (depression) states caused by the autism and effectively adsorb the PCBs.